


Book early and save up to \$500



AED 2013

8TH ANTIBODY ENGINEERING & DISCOVERY

BOSTON

Discover Superior Leads, Optimize Desired Properties, Transform Clinical Performance

23rd – 25th July | Boston, Revere Boston Common

Benefits of attending

- Hear from 25 pioneering industry thought-leaders as they outline **dozens of radical new approaches to help you discover and engineer antibodies** with superior biophysical and functional properties
- Learn how to use **innovative differentiation technologies** in a commercial environment, to **develop therapeutic antibodies faster, at a lower cost and with higher efficacy**
- **Network and learn** from an audience focused on discovery and engineering, and consisting of **over 70% drug developers***, helping you take away useable information that you can use directly on your return to the lab * 71% attendance drug developers in 2012
- **Get the latest insights from the FDA**, as they discuss where drug developers should be focusing their attention as approaches and formats adopted by industry continue to evolve

Workshops: 23rd July 2013

- A) Exploring Future Potential and Applications of Next Generation Sequencing in Antibody Engineering and Discovery.
Richard Shimkets, President and CEO, **Abeome Corporation**
- B) Latest Advances in Reducing the Risk of Immunogenicity: Deimmunization and Tolerance Induction
Anne DeGroot, CEO, **EpiVax, Inc.**
- C) Designing Better Antibodies
Juan Carlos Almagro, Senior Director, Center for Therapeutic Innovation, **Pfizer**
Sreekumar Kodangattil, Senior Principal Scientist, **Pfizer**

Program Partner



25 expert speakers including



Kathleen Clouse-Strebel
Director, Division of Monoclonal Antibodies
FDA



Ira Pastan
Head, Molecular Biology Section
NCI, NIH



George Georgiou
Professor
University of Texas, Austin



Bill Strohl
Vice President, Biologics Research
Johnson & Johnson



Jonny Finlay
Associate Director, Discovery Research
Pfizer



David Meininger
Executive Director, Discovery Research
Merck



Alexey Lugovskoy
Director of Therapeutic Antibody Design
Merrimack



Tariq Ghayur
Senior Research Fellow
AbbVie



Dan Lightwood
Senior Group Leader, Antibody Discovery
UCB



Claire Dobson
Associate Director, Antibody Discovery and Protein Engineering
MedImmune

New & Groundbreaking Insights From:



Juan Carlos Almagro
Senior Director,
Center for Therapeutic
Innovation
Pfizer

Juan Carlos work focuses on the development and application of technologies to engineer the next generation of medicines inspired by biotherapeutics. He has authored over 50 publications.



Randall Brezski
Senior Scientist
Janssen

Randy was a post doc at Centocor in a Research Scientist position within the Fc engineering group, where he worked on developing a novel Fc "silent" monoclonal antibody platform.



Kathleen Clouse-Strebel
Director, Division of
Monoclonal Antibodies
FDA

Kathleen is Director of the Monoclonal Antibodies Division within the FDA. She will be discussing the steps drug developers can take to minimize regulatory concerns around antibody formats in development.



Ray Camphausen
Associate Vice
President, Protein
Design
Adnexus Therapeutics

Ray has served as Associate Vice President, Protein Design since June, 2008. Prior to Adnexus, he served as Vice President, Research & Discovery at Thios Pharmaceuticals, Inc., a biotechnology start-up in California.



Caroline Colley
Senior Scientist, Lead
Generation
MedImmune

Caroline leads a team that has responsibilities for isolation, optimization and functional characterization of candidate therapeutic biologic drugs, and also lead early stage drug discovery projects.



Anne De Groot
CEO & CSO
EpiVax

Anne co-founded EpiVax in 1998, and has been CEO/CSO of the company ever since. She is originally known for her contributions to the fields of immunoinformatics and vaccinology, and has adding expertise in autoimmunity and tolerance.



Claire Dobson
Associate Director,
Antibody Discovery and
Protein Engineering
MedImmune

Claire joined CAT in 2000 and has over thirteen years experience in phage and ribosome display and antibody engineering. She was a member of the team that delivered Benlysta® and also contributed to the discovery of Mapatumumab and Lexitumumab.



Jonny Finlay
Associate Director,
Discovery Research
Pfizer

Jonny is responsible for the discovery and molecular engineering of protein therapeutics for use in indications across all Pfizer Research Units. Prior to Pfizer, Jonny researched recombinant protein engineering at several institutes, including CBER, FDA.



Ivan Correia
Principal Research
Scientist, Protein
Analytics
AbbVie

Prior to joining AbbVie, Ivan was a CSO at a start-up developing drugs for Alzheimer's Disease. Ivan is lead analytical scientist for commercial, late phase and products early in development.



George Georgiou
Professor
**University of Texas,
Austin**

George is a member of the National Academy of Engineering and the American Academy of Microbiology and has received numerous international awards.



Tariq Ghayur
Senior Research Fellow
AbbVie

Tariq holds multiple patents and is the author of several ground-breaking peer-reviewed publications. He has a long history of successfully leading therapeutic antibody discovery teams.



Jaafar Haider
Senior Scientist,
Antibody Technology
ImClone Systems

Jaafar joined the Antibody Technology Department at ImClone Systems to work on antibody humanization and optimization. His role in ImClone is focused on engineering novel biologics for use in cancer therapy across the Lilly Oncology Business Unit.



Mitchell Ho
Chief, Antibody Therapy
Section
**National Cancer
Institute (NCI)**

Mitchells is Chair of the NIH Antibody Interest Group and a recipient of the 2011 NCI Director's Intramural Innovation Award for Principal Investigators. His current work focuses on cancer pathogenesis and antibody-based therapy development.



Dan Lightwood
Senior Group Leader,
Antibody Discovery
UCB

During his 13 years at UCB, Dan has played a key role in developing UCB's antibody discovery platform and has been responsible for successfully applying the technology across a number of UCB therapeutic antibody programs.



Alexey Lugovskoy
Director of Therapeutic
Antibody Design
Merrimack

Alexey is a Senior Director of Therapeutic Design at Merrimack Pharmaceuticals. He is a co-author of 40 manuscripts, 34 patent applications and 1 book chapter, and he received his Ph.D. in Biophysics from Harvard University.



David Meininger
Executive Director,
Molecular Discovery
Merck

Dave is champion of the Adimab collaboration, and co-champion of the Ambrx antibody-drug conjugate collaboration. He is responsible for oversight of lead generation in support of biotherapeutic programs spanning multiple indications.



Ira Pastan
Head, Molecular
Biology Section
**National Cancer
Institute (NCI)**

Ira is a multi-award winning scientist. Scientific milestones credited to Ira include the first example of a positive control of gene expression, groundbreaking research leading to the discovery of the endosome, and the discovery of mesothelin.



Peter Pavlik
Senior Scientist
MedImmune

Peter undertakes antibody lead isolation in several different disease areas. His specialties are HT panning and screening of antibodies from phage libraries and hybridomas, laboratory automation, HT screening assays and automated sample and data tracking.



Sarah Rue
Senior Scientist, Antibody
Therapeutics
**Genomics Institute of
the Novartis Research
Foundation**

Sarah leads a team of scientists responsible for therapeutic antibody discovery and optimization, as well as engineering alternative antibody formats.



Grant Shimamoto
Senior Scientist
Amgen

Grant is currently a group leader in the department of Biologics Optimization, responsible for pipeline support of discovery programs involving protein production and modification/engineering for several different therapeutic areas at Amgen.



Richard Shimkets
President and CEO
Abeome Corporation

Richard serves as the President and CEO of Abeome Corporation. Prior to joining Abeome, he served as VP of Drug Discovery and VP of Scientific Development for CuraGen.



Brenda Stevens
Senior Scientist, Protein
Engineering
Bristol-Myers Squibb

Brenda is currently responsible for leading the protein engineering efforts for therapeutic candidate optimization, including; lead candidate molecule design, reagent generation for *in vivo* studies, and candidate molecule characterization.



Bill Strohl
Vice President, Biologics
Research
Johnson & Johnson

Bill has over 100 publications, owns several patents and has held a variety of leadership roles in both academia & industry.



Dongxing Zha
Research Fellow and Group
Leader, Protein Engineering
Merck

Before the Merck acquisition of GlycoFi, Dongxing worked on glycoengineering yeast and their utility as a host for antibody expression. Dongxing has co-authored many papers in peer reviewed journals and books, and filed multiple US and international patents.

Create Better & Differentiated Antibodies

As competition increases, differentiation in antibody discovery and engineering has never been more important. It's becoming critical to understand how to make new differentiating technologies work in a pressured, commercial environment.

AED 2013 is unique because it **focuses on the needs of drug developers**. It is designed to help you **optimize the clinical potential** of every single antibody candidate in your pipeline. To understand how other drug developers are using new and existing discovery and engineering technologies to **achieve better, differentiated antibodies**.

How will AED 2013 help you create the best antibody candidates?

AED 2013 will deliver useable information that makes a valuable difference to the performance of your business. That means a commitment to high speaker calibre, and **unbeatable opportunities for knowledge sharing and networking**.

Speakers are selected through referral only, for their pioneering work and willingness to challenge existing approaches. Plus, to ensure the quality of interaction is high, **attendee numbers are restricted to 100**. The audience is weighted so **at least 70% of the audience are drug developers**.

AED 2013 will give you the opportunity to discuss your current priorities with peers and receive 1:1 guidance from leading minds in the field of commercial antibody development.

- Hear **George Georgiou** and **Ira Pastan** outline ground-breaking new discovery and engineering approaches that will change the way you operate.
- Get valuable insights into the latest efforts of **MedImmune**, **Pfizer**, **Merck** and **UCB** in modifying their discovery approaches to deliver better candidates.
- Understand how to adapt the most recent approaches taken by **Janssen**, **Merrimack**, **Bristol-Myers Squibb** and **Novartis** to enhance biophysical and functional properties.
- Leverage new computational approaches to assist antibody engineering and enhance design outcomes, with groundbreaking information from **ImClone Systems** and **Pfizer**.
- Discover innovative ways of developing new, antibody-based formats that overcome the limitations of classical antibodies, from **AbbVie**, **BMS**, **Amgen** and **Merck**.

Join the Therapeutic Antibody Community

Following the success of previous meetings, we'd like to extend a warm welcome back to our regular attendees, as well as greet new:

- **Directors** and **Heads of antibody discovery, protein engineering, biologics and drug discovery** at large pharmaceutical and biotech companies.
- **Researchers** and **scientists** dedicated to developing more effective antibody drugs through innovative discovery, selection and engineering approaches.
- **CEOs, CSOs** and **Heads of antibody development** at pioneering and innovative biotech.
- Providers of **platform technologies** that are relevant for antibody discovery, selection and engineering.
- Preclinical **CROs, equipment** and **reagent** suppliers.



Search groups for: **Antibody Engineering and Discovery Forum** to join the online community.

Hear what previous Hanson Wade attendees have to say

"High quality speakers, high content presentations and lots of opportunities for networking"

Juan Carlos Almagro
Senior Director, Center for Therapeutic Innovation
Pfizer

"Great meeting. Open and informal discussion sharing experiences around the similar challenges we face in discovering antibody drugs"

MedImmune

"Networking is key for my business. Thanks for providing opportunities"

GSK

"Great talks, good networking, very open discussions"

EMD Serono

"A good venue for a reviewing the antibody engineering industry and opportunities to learn about new breakthroughs"

AbbVie

"Nice agenda, top notch speakers, and great presentations and speed networking"

Aldevron

Day 1

24th July 2013

8.00 Registration, Coffee & Networking

9.00 A FDA Update on the Development of Therapeutic mAbs and Their Alternatives

- Understanding existing and novel antibody formats and characteristics that are most favoured
- How you can address areas of concern that are increasing in frequency of occurrence

Kathleen Clouse-Strebel, Director, Division of Monoclonal Antibodies, **FDA**

9.30 Next Generation Technologies for Antibody Discovery and Engineering: A Radical New Approach for Engineering Antibody Therapeutics

- The discovery of potent, biologically active antibodies via mining of the serum antibody repertoire.
- The use of engineered aglycosylated Fc domains to impart completely novel and enhanced effector function

George Georgiou, Professor, **University of Texas, Austin**

10.00 Speed Networking & Morning Refreshments

A revolutionary and highly valued way to meet fellow attendees in a 60 minute session. Bring lots of business cards!



Digging for Diamonds: Finding the Optimal Antibody Leads

11.30 Efficient Mining of the Immune B Cell Repertoire to Generate High-Quality Monoclonal Antibodies

- A novel antibody discovery process that enables extremely efficient sampling of the B-cell repertoire
- Identification and isolation of individual antigen-specific B-cells from heterogeneous populations

Dan Lightwood, Senior Group Leader, Antibody Discovery, **UCB**

12.00 A Novel Transgenic Mouse System for the Comprehensive Characterization of an Antibody Immune Response

- Generation of a transgenic system for enabling efficient antigen selection of antibody-producing cells
- Next-gen sequencing approach to characterizing antigen-specific repertoires; applications for target screening

Richard Shinkets, President and CEO, **Abeome Corporation**

12.30 Networking Lunch

1.30 Case Study: Comprehensive Interrogation of a Minimalist Synthetic CRD-H3 Library and its Ability to Generate Antibodies with Therapeutic Potential

- Creating large synthetic scFV libraries built using a single framework pair
- The critical association between CDR length and stem diversity, and functional library content

William Finlay, Associate Director, Discovery Research, **Pfizer**

2.00 Moving Your Therapeutic Antibody Discovery Capability Forward

- The merits and limitations of discovery approaches and platforms, and addressing diversity

George Georgiou, **University of Texas, Austin**; **David Meininger**, **Merck**; **Peter Pavlik**, **MedImmune**

Developing Antibodies for New and Challenging Targets

2.30 Isolating/Optimizing mAbs to Challenging Targets

- Isolating functional antibodies to GPCRs and ion channels, and challenges around conformation, expression and antigenicity

Caroline Colley, Senior Scientist, Lead Generation, **MedImmune**

3.00 Case Study: Generation of Novel Human Single-Domain Antibodies Targeting Glypican-3 and Mesothelin for Cancer Therapy

- Generation of appropriate single-domain antibodies against novel cancer targets
- Demonstration of functional antibodies that disrupt oncogenic signalling

Mitchell Ho, Chief, Antibody Therapy Section, **National Cancer Institute**

3.30 Afternoon Refreshments Networking

Understanding and Optimizing Bispecific Formats

4.30 Case Study: Engineering of IL-23/IL-17A/F Neutralizing Bispecific Antibodies

- An overview of a multi-specific antibody that presents an innovative therapeutic for inflammatory disorders
- Evaluation of novel and validated bispecific antibody-like formats

Brenda Stevens, Senior Scientist, Protein Engineering, **Bristol-Myers Squibb**

5.00 High Resolution Imaging Techniques to Reveal Protein and Cell Dynamics

- Imaging dynamics of the DVD-IG molecules, and implications for the design of other protein therapeutics

Ivan Correia, Principal Research Scientist, Protein Analytics, Process Sciences, **AbbVie**

5.30 Managing the Risks and Benefits of Engineering Different Bispecific Formats

- Key considerations and lessons learned from developing bispecific formats

Dongxing Zha, **Merck**; **Brenda Stevens**, **Bristol-Myers Squibb**; **Tariq Ghayur**, **AbbVie**; **Ivan Correia**, **AbbVie**

6.00 Close of Day & Networking Drinks



Day 2

25th July 2013

8.00 Registration, Coffee & Networking

9.00 Biology First! Putting Therapeutic Antibody Engineering into the Context of Past, Present, and Future Developments

- Considering antibody discovery and engineering – key lessons and their implications for drug developers
- Assessing the importance of the targets – predictions for the future

Bill Strohl, Vice President, Biologics Research,
Johnson & Johnson

9.30 Immunotoxin Treatment of Leukemia and Mesothelioma

- An outline of the composition and mechanism of action of recombinant immunotoxins (RITs)
- Response to RIT Moexetumomab pasudotox in patients with drug resistant Hairy Cell Leukemia and children with refractory acute lymphoblastic leukemia
- Development of RITs to treat solid tumors, with decreased immunogenicity and mutations that remove B and T-cell epitopes

Ira Pastan, Head, Molecular Biology Section, Laboratory Chief, Center for Cancer Research, **NCI**

New Approaches for Engineering Antibodies with Desired Properties

10.00 Harnessing Rational Design Strategies to Improve the Stability of Therapeutic Proteins

- Strategies to generate high affinity antibodies
- Overcoming developability challenges
- Improving the physiochemical properties of antibodies through protein engineering

Claire Dobson, Associate Director, Antibody Discovery and Protein Engineering, **MedImmune**

10.30 Morning Refreshments & Networking

11.00 Understanding the Design Characteristics of Antibodies and Antibody-like Molecules to Enable their Focused Optimization for Therapeutic Use

- Using and understanding of the target biology to drive lead identification and therapeutic format selection
- Tackling the complexity of the antibody design space through modular engineering
- Efficient ways of engineering for biological activity and biophysical properties in discovery to minimize the chances of failure in development

Alexey Lugovskoy, Director of Therapeutic Antibody Design, **Merrimack**

11.30 Pharmacokinetic Modulation of Adnectin Therapeutics: Experiences from Bench to Clinic

- Approaches for the modification of Adnectins with improved pharmacokinetics

Ray Camphausen, Associate Vice President, Protein Design, **Adnexus Therapeutics**

12.00 Mastermind Groups

Mastermind groups are an opportunity to discuss pertinent industry challenges and generate solutions through collective experience sharing. Interactive break-out groups work together to discuss and debate key questions, predict future challenges in this space and brainstorm possible solutions.



12.30 Networking Lunch

1.30 Engineering Therapeutic IgG Half-Molecules

- An overview of the modifications required to monomerize hIgGs
- Performance of IgG half molecules in cell-based assays and pharmacokinetic studies

Sarah Rue, Senior Scientist, Antibody Therapeutics, **Genomics Institute of the Novartis Research Foundation**

Leveraging the Convergence of Computational Approaches and mAb Engineering

2.00 Making the Link Between Computational and Experimental: Knowledge-Based Approaches to Antibody Engineering

- Mined antibody structural datasets to unveil the impact of:
 - The framework region on antibody recognition
 - The structural flexibility of CDRs on the affinity of antigen recognition

Jaafar Haider, Senior Scientist, Antibody Technology, **ImClone Systems**

2.30 Afternoon Refreshments & Networking

Novel Engineering and Optimization Approaches to Develop Differentiated, Ground-Breaking Antibodies

3.00 Novel Engineering Insights on Developing Increasingly Effective Antibodies for Cancer Therapies

- Detailing IgG1 proteolysis as a potential immune-evasion mechanism
- Engineering protease-resistant antibodies with selective killing functions

Randall Brezski, Senior Scientist, **Janssen**

3.30 General Perspectives on Peptibody Design, Production and Clinical Utility

- Peptibody definition and history
- Design objectives and an outline of manufacturing considerations
- Clinical considerations for the therapeutic application of Peptibody's.

Grant Shimamoto, Senior Scientist, **Amgen**

4.00 Chairman's Closing Remarks & End of Day Two

Workshop A: Exploring Future Potential and Applications of Next Generation Sequencing in Antibody Engineering and Discovery

Date: 23rd July 2013

Time: 9am – 12pm


Advances in DNA sequencing have made it possible to determine the variable region sequences of entire antibody repertoires in a variety of model systems and in humans.

Translating this massive amount of information into useful commercial antibody products represents a challenging but **extremely rewarding leap forward in antibody development**.

In this workshop you will learn:

1. **Technologies available for antibody repertoire sequencing**
2. **Experimental design for sequence-based studies**
3. **Bioinformatics approaches to analyzing large antibody data sets**

Attend this workshop to discuss your challenges in antibody discovery, engineering and development. Then learn how next-generation sequencing approaches will address them.



Workshop leader

Richard Shimkets
President and CEO
Abeome Corporation

Richard Shimkets, PhD. serves as the President and CEO of Abeome Corporation. Prior to joining Abeome, he served as Vice President of Drug Discovery and Vice President of Scientific Development for CuraGen Corporation. He developed and managed partnerships with Genetech, Biogen, Bayer, and other biotechnology and pharmaceutical companies.

Workshop B: Latest Advances in Reducing the Risk of Immunogenicity: Deimmunization and Tolerance Induction

Date: 23rd July 2013

Time: 12.30pm – 3.30pm

Deimmunization is currently practiced by protein engineers to render biologics less immunogenic in the clinic. And the recent discovery of **Tregitopes** has had a profound impact on the design of biologics. **Many companies have now integrated both Treg epitope and T effector epitope screening** into their approach to biologics.

In this workshop, you will learn how to:

1. **Factors that contribute to immunogenicity**
2. **Methods for screening biologics *in vitro* and *in silico***
3. **Identification of Tregs by FACS, cytokine profiling and expression of FoxP3**
4. **Expansion of antigen-specific regulatory T cells (adaptive Tregs)**

Experienced users will describe the application of web-based immunoinformatics tools to their pre-clinical pipeline. An online demonstration of the ISPRI system will be provided for workshop participants.



Workshop leader

Anne DeGroot
CEO
EpiVax

Anne co-founded EpiVax in 1998 and has been CEO/CSO of the company since. Although Anne is known for her contributions to the fields of immunoinformatics and vaccinology, the discovery of Tregitopes by the EpiVax research team in 2008 resulted in a shift in her research efforts, adding new explorations in autoimmunity and tolerance.

Workshop C: Designing Better Antibodies

Date: 23rd July 2013 Time: 4pm – 7pm

To make therapeutic antibodies **faster, at a lower cost but with higher efficacy**, the designing principles to **enhance potency, cross-reactivity, solubility and other important properties of the therapeutic antibodies** are constantly being improved.

This knowledge, together with the (I) full characterization of the germline gene antibody repertoire, (II) faster and more user friendly antibody modeling methods, and (III) development of technologies capable of generating sequence information of repertoires at low cost, are leading to implementation of more effective designs.

In the workshop you will learn:

1. **The state of the art of antibody modeling**
2. **Designing principles and computational tools to engineer more developable antibodies**
3. **Bioinformatic approaches to analyzing large antibody data sets**



Workshop leader

Juan Carlos Almagro
Senior Director, Center for
Therapeutic Innovation
Pfizer

Juan Carlos's work focuses on the development and application of technologies to engineer the next generation of biotherapeutics. He has been active in the antibody and protein engineering fields since the beginning of the 1990's, with more than ten years of experience in academic settings and over six years of experience in the Pharma/Biotech industry.

Sponsorship Opportunities



Miles Harley

If your organization needs to raise profile, promote products and services or develop new partnership opportunities in the **antibody** sector, contact:

tel: +44 (0)20 3141 8797

email: mharley@hansonwade.com

Working with Hanson Wade


When you work with Hanson Wade you work with a partner focused on your success. Your investment in both time and money needs to generate a return.

Our clients want that too and that's why they work with us. They want to reach a targeted audience and eliminate wastage from their marketing activities. They work with us because we deliver results. We're proud of this fact.

Our research identifies ground breaking issues and allows you to influence industry thinking at an early stage. Our expertise is recognised and respected by the industry. And our events are focused, leading edge and attended by people looking for knowledge before making decisions.

Attendee Breakdown

Breakdown of Last Year's Attendees




Program Partner




Abeome Corporation

Abeome Corporation develops, manufactures, and partners proprietary monoclonal antibody technology for use in the biotechnology industry. Abeome has developed two different antibody technologies. Direct Selection of Hybridomas (DiSH) technology utilizes genetically engineered myeloma fusion partners that produce hybridomas that surface-express and secrete antibody. DiSH kits are distributed for Abeome by Enzo Life Sciences. Abeome's transgenic AbeoMouse(TM) technology produces large quantities of B cells that both surface express and secrete antibody, for use in antibody discovery primarily on therapeutic targets where high affinity neutralizing antibody repertoires are sought rapidly.

Media Partners



Seniority Breakdown of Last Year's Attendees



AED 2013

Boston

23rd – 25th July 2013

Priority Code:

WEB

Register

Online: www.antibody-engineering.com**Tel:** +1 212 537 5898**Fax:** +1 212 537 5898**Email:** info@hansonwade.com**Mail:**

Hanson Wade
304 Park Avenue South
11th Floor
New York, NY 10010

Team Discounts

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Venue and Accommodation

Venue

Revere Hotel, Boston Common
200 Stuart Street, Boston, MA 02116

Accommodation

Overnight accommodation is not included in the registration fee, however accommodation options will be sent out with your confirmation email upon registering.

Event Prices

Package	Register and pay before: Friday 3rd May *	Register and pay before: Friday 7th June*	Standard Price*
Standard Pricing			
☐ 2 Day Conference +3 workshops	\$3698 (SAVE \$500)	\$3798 (SAVE \$400)	\$3898 (SAVE \$300)
☐ 2 Day Conference +2 workshops	\$3197 (SAVE \$400)	\$3297 (SAVE \$300)	\$3397 (SAVE \$200)
☐ 2 Day Conference +1 workshop	\$2698 (SAVE \$300)	\$2798 (SAVE \$200)	\$2998
☐ 2 Day Conference	\$2199 (SAVE \$200)	\$2299 (SAVE \$100)	\$2399
☐ Workshop (each)	\$599		
Please select your choice of workshop: Workshop A ☐ Workshop B ☐ Workshop C ☐			

*All discount offers (including team discounts) require payment at the time of registration to receive any discount. 'Early Bird' discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

Delegate Details

Title:	Forename:	Surname:
Job Title:	Company/Organization:	
Email:	Direct Manager:	
Address:	Postcode:	
Country:	Direct Telephone:	
Direct Fax:	Mobile:	
Switchboard:	Signature:	Date:

Payment Details

Number of delegates: ☐	Amount: \$ _____	Conference Documentation: ☐	Credit Card: ☐	Visa ☐	Mastercard ☐	Amex ☐
Card No:	Valid from:	Expiry Date:				
Cardholders name: _____						
Signature: _____						Date: _____
Card billing address: _____						

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ

Hanson Wade Limited. Registered in England & Wales. Company No: 6752216

Tel: +1 212 537 5898 **Fax:** +1 212 537 5898 **Email:** info@hansonwade.com
www.antibody-engineering.com



Code: 3454